Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Score, Valuation & Financial Research

Acrivon Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ACRV

Acrivon Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 1.86. These figures are a research snapshot, not a buy or sell recommendation.

What Acrivon Therapeutics, Inc. Common Stock does

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Acrivon Therapeutics is a clinical-stage biopharmaceutical company that generates no product revenue. It focuses on developing precision oncology medicines using its proprietary AP3 platform to identify patients likely to respond to its drug candidates, with the goal of future commercialization through regulatory approval and potential partnerships.

Products and services

  • The company is developing a pipeline of precision oncology candidates, most notably ACR-368, a targeted DNA damage response inhibitor, and ACR-6840, utilizing its AP3 platform for drug design and patient selection.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of its drug candidates for clinical trials; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Biopharmaceutical and biotechnology companies — The company competes with various entities developing oncology therapeutics, including those focused on DNA damage response inhibitors and precision medicine. Source

Business strengths to evaluate

  • Proprietary AP3 platform for precision medicine development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ACRV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.86
Market capitalization:
79.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -74.23M
Free cash flow:
USD -65.33M
Cash:
USD 41.42M
Total debt:
USD 2.12M
EPS:
USD -1.88

What stands out

  • Free cash flow is USD -65.33M, negative for the stored period.
  • The balance sheet shows USD 41.42M of cash versus USD 2.12M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 39.3M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ACRV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ACRV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ACRV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ACRV to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ACRV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ACRV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.